COMPANY PROFILE

Immune Targeting Systems

Immune Targeting Systems develops synthetic vaccines for mutating viruses, improving the quality of life for those infected by viruses

Great Barrington, United StatesFounded 2003Biotech & Life Sciences

Valuation $50–100M Last recorded · 2010

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Immune Targeting Systems

Altimmune is a clinical-stage biopharmaceutical company dedicated to developing advanced treatments for liver disease, chronic Hepatitis B, and cancer, along with intranasal vaccines for infectious diseases such as anthrax, influenza, and COVID-19. The company operates in the biopharmaceutical market, focusing on creating novel therapies that address significant unmet medical needs. Altimmune's business model revolves around research and development, progressing through clinical trials, and eventually seeking regulatory approval for its diverse pipeline of therapeutic candidates. Revenue generation is anticipated through the commercialization of these therapies, either independently or through strategic partnerships and collaborations with other pharmaceutical companies. The primary clients include healthcare providers, hospitals, and patients requiring specialized treatments for the aforementioned conditions. Altimmune's innovative approach and commitment to addressing critical health challenges position it as a key player in the biopharmaceutical industry.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2003
Headquarters: Great Barrington, United States
Open positions: None listed
Dealroom signal: 20.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Vaccines, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Feb 2015	$0	—	Altimmune	—
SERIES A✓Equity / VC	Mar 2010	$13M	$53M	Novartis Venture Fund	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Immune Targeting Systems website traffic

Latest recorded traffic for Immune Targeting Systems is 0 monthly website visits.

Latest monthly visits0

Monthly website visitsApr 2016–May 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
LMLatch MedicalA new approach to drug and vaccine delivery	Dublin, Ireland	Operational	9	—	—
SASapVaxDeveloping a suite of first-in-class cancer vaccines based on a novel self-adjuvanting peptide platform technology	Cleveland, United States	Operational
TRTransAlgaeDevelops an algae-based platform for oral delivery of high value products for Animal Health and Crop Protection	Rehovot, Israel	Operational
SVSolaris VaccinesA biotechnology company that develops therapeutic vaccines for infectious diseases	Fort Collins, United States	Operational
ITIaso TherapeuticsStartup that is dedicated to developing next generation vaccines to enhance human health and treat diseases	East Lansing, United States	Operational
THThyreosThyreos Vaccines \| Bovine Respiratory Disease	Lincoln, United States	Operational
DEDesentumBiopharma company in Finland developing allergy vaccines that change the way the immune system reacts to allergens	Espoo, Finland	Operational
BSBotanical SolutionsDeveloping botanical products that are sustainable and cost-effective	Amherst, United States	Operational